This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
The Looming Challenge to U.S. Competitiveness
Porter, Michael E.; Rivkin, Jan W.Article HBS-R1203B-EStrategyAlthough the U.S. retains profound competitive strengths--for instance, in higher education and entrepreneurship--those strengths are increasingly threatened by weaknesses in areas such as the tax code, basic education, macroeconomic policies, and regulation. Steps to reverse the loss will require a new focus by government and business leaders.Starting at €8.20
-
Choosing the United States
Porter, Michael E.; Rivkin, Jan W.Article HBS-R1203F-EStrategyA location decision is, in many respects, a referendum on a nation's competitiveness. When a company decides, say, to build a new plant in China rather than in the United States, it is effectively voting on the question of which country can best enable its success in the global marketplace. Over the past three decades, business activities have become increasingly mobile, and more and more countries have become viable contenders for them. But new ...Starting at €8.20
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCase HBS-313069-EStrategyThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Starting at €8.20
-
Angel Investments in Europe and Recent Developments in Crowdfunding
Applegate, Lynda M.; Dessain, Vincent; Billaud, Emilie; Beyersdorfer, DanielaCase HBS-814047-EEntrepreneurshipThis technical note provides information on the evolution and current state of angel investing in Europe. The note first describes the role and types of angel investors, focusing on their investment preferences and practices. It then details the new trends in the market, including the development of policy tools and the proliferation of incubators/accelerators to support angel investors. Finally, the note explores salient issues in angel investin...Starting at €8.20
-
Go Beyond Investing
Applegate, Lynda M.; Dessain, Vincent; Billaud, Emilie; Beyersdorfer, DanielaCase HBS-814046-EEntrepreneurshipIn 2013, Brigitte Baumann, founder of the Pan-European angel investing provider Go Beyond Investing, reflected on the evolution of her venture and the way forward. Her company, which offered deal flow and training to novice and experienced angel investors and ran investor groups in several European countries, had reached a critical size, and Baumann needed to make a strategic decision to ensure its future growth in an industry that was undergoing...Starting at €8.20
-
Matching Dell (Spanish version)
Rivkin, Jan W.; Porter, Michael E.Case HBS-702S06StrategyAfter years of success with its vaunted "Direct Model" for computer manufacturing, marketing, and distribution, Dell Computer Corp. faces efforts by competitors to match its strategy. The case 'Matching Dell' describes the evolution of the personal computer industry, Dell's strategy, and efforts by Compaq, IBM, Hewlett-Packard, and Gateway 2000 to capture the benefits of Dell's approach. Students are called on to formulate strategic plans of acti...Starting at €8.20
-
Industry Transformation (Spanish version)
Porter, Michael E.; Rivkin, Jan W.Case HBS-703S24StrategyDesigned to support course modules that consider strategy-making under uncertainty or the intersection of competitive strategy and technology.Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
LEGO, Teaching Note
Thomke, Stefan; Rivkin, Jan W.Teaching Note HBS-614008-ETeaching Note for 614008.Starting at €0.00
-